Purified CARCIK-CD19 or unmodified CIK with the addition of blinatumomab were then evaluated for their ability to mount an in vitro anti-leukemia cytotoxic response against two CD19+ cell lines, the B-ALL REH and the Burkitt lymphoma Daudi. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.